A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Pértega Gomes, Nelma ^a,b   Vizcaíno, José R ^c   Attig, Jan ^d   Jurmeister, Sarah ^e   Lopes, Carlos ^c,f   Baltazar, Fátima ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c Centro Hospitalar Universitario do Porto   (Portugal)

^d MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF PORTO   (Portugal)

Author keywords

Cancer associated fibroblasts; Monocarboxylate transporters; Poor prognosis; Prostate cancer

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ACYL COENZYME A OXIDASE; CARBONATE DEHYDRATASE IX; CELL PROTEIN; D BIFUNCTIONAL PROTEIN; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUT12 PROTEIN; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE 5; LACTIC ACID; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PRISTANOYL ACYL COENZYME A OXIDASE; PYRUVIC ACID; TUMOR MARKER; UNCLASSIFIED DRUG; COTRANSPORTER; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; MONOCARBOXYLATE TRANSPORT PROTEIN 1; MONOCARBOXYLATE TRANSPORTER; MUSCLE PROTEIN; PROSTATE SPECIFIC ANTIGEN; SLC16A4 PROTEIN, HUMAN;

ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; FATTY ACID OXIDATION; GLUCOSE TRANSPORT; GLYCOLYSIS; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LACTATE SHUTTLE SYSTEM; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; OXIDATIVE STRESS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; STROMA CELL; TISSUE SECTION; TRANSPORT AT THE CELLULAR LEVEL; BLOOD; CHEMISTRY; ENERGY METABOLISM; FIBROBLAST; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

BIOLOGICAL TRANSPORT; ENERGY METABOLISM; FIBROBLASTS; HUMANS; KALLIKREINS; LACTIC ACID; MALE; MIDDLE AGED; MONOCARBOXYLIC ACID TRANSPORTERS; MUSCLE PROTEINS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; STROMAL CELLS; SYMPORTERS; TREATMENT OUTCOME;

EID: 84901597401     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-352     Document Type: Article

References (25)

1. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick AC. The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int 2010, 105(1):8-13.
2. Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Pinover WH, Greenberg RE, Stobbe C, Hanks GE. Hypoxia in human prostate carcinoma: an Eppendorf PO2 study. Am J Clin Oncol 2001, 24(5):458-61.
3. Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997, 3(2):177-82.
4. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989, 49(16):4373-84.
5. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Dieport C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008, 118(12):3930-42.
6. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Scmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr 2012, 44(1):127-39.
7. Enerson BE, Drewes LR. Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J Pharm Sci 2003, 92(8):1531-44.
8. Halestrap AP, Wilson MC. The monocarboxylate transporter family-role and regulation. IUBMB Life 2012, 64(2):109-19.
9. Busk M, Horsman MR, Kristjansen PE, van der Kogel AJ, Bussink J, Overgaard J. Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer 2008, 122(12):2726-34.
10. Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009, 19(1):12-6.
11. Potter CP, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003, 89(1):2-7.
12. Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, Luo J, De Marzo AM, Isaacs WB. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 2005, 63(4):316-23.
13. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 2006, 9(3):230-4.
14. Koukourakis MI, Giatromanolaki A, Bougioukas G, Sivridis E. Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. Cancer Biol Ther 2007, 6(9):1476-9.
15. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res 2006, 66(2):632-7.
16. Whitaker-Menezes, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, Birbe RC, Howell A, Pavlides S, Gandara R, Pestell RG, Sotgia F, Philp NG, Lisanti MP. Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 2011, 10(11):1772-83.
17. Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De Donatis A, Lanciotti M, Serni S, Cirri P, Chiarugi P. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res 2012, 72(19):5130-40.
18. Giatromanolaki A, Koukourakis MI, Koutsopoulos A, Mendrinos S, Sivridis E. The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biol Ther 2012, 13(13):1284-9.
19. Pertega-Gomes A, Vizcaino JR, Miranda-Goncalves V, Pinheiro C, Silva J, Pereira H, Monteiro P, Henrique RM, Reis RM, Lopes C, Baltazar F. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer 2011, 11:312.
20. Cooper RP, Aslin RN. The language environment of the young infant: implications for early perceptual development. Can J Psychol 1989, 43(2):247-65.
21. Cramblit NS, Siegel GM. The verbal environment of a language-impaired child. J Speech Hear Disord 1977, 42(4):474-82.
22. Condon MS. The role of the stromal microenvironment in prostate cancer. Semin Cancer Biol 2005, 15(2):132-7.
23. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 2005, 65(19):8887-95.
24. Arnold JT, Gray NE, Jacobowitz K, Viswanathan L, Cheung PW, McFann KK, Le H, Blackman MR. Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells. J Steroid Biochem Mol Biol 2008, 111(3-5):240-6.
25. Morrissey C, Vessella RL. The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem 2007, 101(4):873-86.